

COMPANY OVERVIEW

Avalo Therapeutics is a biopharmaceutical company developing innovative therapies. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare diseases and immune-mediated inflammatory disorders.

RECENT NEWS

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Dec 8 2020, 7:00 AM EST

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II

Dec 1 2020, 7:00 AM EST

STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	205.65m
Last Price	\$2.70
52-Week Range	\$1.52 - \$6.19

12/09/2020 11:45 AM EST

INVESTOR RELATIONS

ir@avalotx.com

MANAGEMENT TEAM

Michael Cola

Chief Executive Officer

James A. Harrell, Jr.

Chief Commercial Officer

Lisa Hegg Ph.D.

Vice President Research and Development Program and Project Management

Colleen Matkowski

Vice President Global Regulatory Affairs

Garry Neil, MD

Chief Scientific Officer

Younok Dumortier Shin, PhD, MBA

Chief Technology Officer

Chris Sullivan

Interim Chief Financial Officer

H. Jeffrey Wilkins, MD

Chief Medical Officer

AVALO THERAPEUTICS

1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.